Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

<< Previous

Bullboard Posts

Next >>

Post by stephanedodieron Dec 20, 2022 3:42pm

138 Views

Post# 35183040

Question for SPCEO

If you have the time and the numbers...

I know that the Bloomberg sales numbers are often not representive but I would be curious to compare Bloomberg FY2021 sales against last year income statement, and to apply the same fudge factor to this year bloomberg FY2022 sales number. It Bloomberg sales numbers are off they should be off with the same % this year, and I know that those monthly sales numbers must be available.

This could help us have an idea of that the top line will look like, (not the cost I know).

I hope thait my question is clear ?

Thanks

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks